Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Inv. presentation
Director departure

Cyteir Therapeutics, Inc. (CYT) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/12/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
10/12/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
10/12/2023 8-K Quarterly results
10/05/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
Docs: "99 Hayden LLC, a Delaware limited liability company , and Cyteir Therapeutics, Inc., a Delaware corporation . Background"
10/02/2023 PREM14A Form PREM14A - Preliminary proxy statements relating to merger or acquisition:
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/03/2023 SC 13D/A Novo Holdings A/S reports a 4.4% stake in Cyteir Therapeutics, Inc.
07/26/2023 SC 13D/A Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
07/20/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/18/2023 4 Novo Holdings A/S (10% Owner) has filed a Form 4 on Cyteir Therapeutics, Inc.
Txns: Sold 11,000 shares @ $2.7365, valued at $30.1k
Sold 21,100 shares @ $2.7488, valued at $58k
Sold 6,500 shares @ $2.7574, valued at $17.9k
07/14/2023 144 Form 144 - Report of proposed sale of securities:
07/10/2023 SC 13G/A FMR LLC reports a 2.3% stake in CYTEIR THERAPEUTICS INC
07/03/2023 4 Novo Holdings A/S (10% Owner) has filed a Form 4 on Cyteir Therapeutics, Inc.
Txns: Sold 200,937 shares @ $2.6341, valued at $529.3k
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
06/30/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Cyteir Therapeutics Announces Discontinuation of CYT-0851 Development Program and Planned Liquidation and Dissolution"
06/28/2023 4 Novo Holdings A/S (10% Owner) has filed a Form 4 on Cyteir Therapeutics, Inc.
Txns: Sold 8,437 shares @ $1.7905, valued at $15.1k
Sold 31,978 shares @ $1.7727, valued at $56.7k
06/28/2023 144 Form 144 - Report of proposed sale of securities:
06/12/2023 144 Form 144 - Report of proposed sale of securities:
05/31/2023 8-K Resignation/termination of a director
05/10/2023 10-Q Quarterly Report for the period ended March 31, 2023
04/27/2023 ARS Form ARS - Annual Report to Security Holders:
04/27/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/27/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/03/2023 8-K Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...
Docs: "Agreement”) is made as of March 29, 2023 , by and between 99 HAYDEN LLC, a Delaware limited liability company , and CYTEIR THERAPEUTICS, Inc., a Delaware corporation . RECITALS:"
03/23/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
03/23/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/23/2023 8-K Quarterly results
Docs: "Cyteir Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights - Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 - Dose for the Phase 1 combination trials identified as 400mg daily - Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026"
02/14/2023 SC 13G BAKER BROS. ADVISORS LP reports a 7% stake in Cyteir Therapeutics, Inc.
02/14/2023 SC 13G/A Avidity Partners Management LP reports a 5.1% stake in Cyteir Therapeutics, Inc.
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/07/2023 4 Zakrzewski Joseph S (Director) has filed a Form 4 on Cyteir Therapeutics, Inc.
Txns: Granted 14,150 options to buy @ $1.69, valued at $23.9k
02/07/2023 4 THERO JOHN F (Director) has filed a Form 4 on Cyteir Therapeutics, Inc.
Txns: Granted 12,828 options to buy @ $1.69, valued at $21.7k
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy